| Clinical data | |
|---|---|
| Other names | CST3056; CuraAX |
| Routes of administration | Oral[2] |
| Drug class | α1-Adrenergic receptor agonist |
CST-3056, also known as CuraAX, is an α1A-adrenergic receptor agonist which is under development for the treatment of neurogenic orthostatic hypotension (nOH) (e.g. due to pure autonomic failure (PAF)), Parkinson's disease, and Alzheimer's disease.[3][2][4] It is taken orally.[2]
The drug is a centrally penetrant selective partial agonist of the α1A-adrenergic receptor.[2][4] nOH frequently occurs in neurodegenerative diseases like Parkinson's disease and Alzheimer's disease and CST-3056 is in part aimed to treat these cases, including to both stabilize blood pressure and improve cerebral perfusion (brain blood flow).[2][4]
CST-3056 is under development by CuraSen Therapeutics.[3][4] As of November 2025, it is in phase 2 clinical trials for treatment of orthostatic hypotension and the preclinical research stage of development for Alzheimer's disease.[3][4] The chemical structure of CST-3056 does not yet appear to have been disclosed.
See also
[edit]References
[edit]- 1 2 3 4 5 "CST-3056". ALZFORUM. 30 December 2025. Retrieved 13 March 2026.
- 1 2 3 "Delving into the Latest Updates on CuraAX". Synapse. PatSnap. 18 September 2025. Retrieved 13 March 2026.
- 1 2 3 4 5 Debbarma S (24 October 2025). "CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension". Clinical Trials Arena. Retrieved 13 March 2026.